BioSpace News Archive

North Central Health Care has selected Cerner Corporation®, a global health care technology company, to implement its electronic health record at three multi-specialty behavioral health care facilities across Wisconsin.

Seclidemstat is currently being studied in a Phase 1/2 clinical trial for Ewing sarcoma, a rare and deadly pediatric bone cancer

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the Biologics License Application (“BLA”) for Danyelza™

NuProbe, a global precision molecular diagnostics company, announces the world-wide exclusive in-license of two technologies from Rice University.

Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), and Duchenne UK, a UK-based patient organization, are pleased to announce the launch of their joint 2020 Research Grant Call, inviting research proposals for submission and review.

Know Labs, Inc. an emerging leader in non-invasive medical diagnostics, announced that it closed a financing round on May 26, 2020.

RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (“RegeneRx”), a clinical-stage drug development company focused on tissue protection, repair and regeneration has posted information on its website regarding the revised schedule for completion of the ARISE-3 dry eye clinical trial, http://www.regenerx.com/2020-06-02-June-2-2020-Advi

- Compatibility plan includes testing representative samples of all commercially available CVCs and PICCs - Plan is designed to be conducted in parallel with the completion of the Phase 3 pivotal trial - Targeted worldwide market for Mino-Lok® is expected to reach $1.84 billion by 2028

Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“ Lattice Biologics ” or the “ Company ”) announces financial results for Q2 2020 Highlights of the Three and Six Months Ended March 31, 2020 Sales and Product Offerings Gross profit margin was 56% for the three months ended March 31, 2020, compared to 77% for the same period in the previous year. Gross profit margin was 57% for the six

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is excited to announce the publication of a health economic study in Wound Management and Prevention, which states that the use of PICO™ Single Use Negative Pressure Wound Therapy System (sNPWT) is estimated to be highly cost effective when compared with traditional NPWT (tNPWT),